Lumos Pharma, Inc. (LUMO) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
May 10, 2022 4:01 PM EDT--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022--
--FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold--
--Clinical Collaboration Initiated with Massachusetts General Hospital for Evaluation of LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in Phase 2 Pilot Trial--
AUSTIN, Texas, May 10, 2022 (GLOBE NEWSWIRE) --... More



